Glenmark Pharmaceuticals SA (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals India, has announced the discovery and initiation of investigational new drug enabling studies for a novel clinical development candidate, targeting oncology indications. The molecule is the second clinical development candidate targeting cancer. The company said the antibody is a well established target for multiple myeloma, a cancer caused by malignant plasma cells, and is potentially also a target for other hematopoietic malignancies. The company has three monoclonal antibodies in the novel biologics entity pipeline undergoing active clinical development.
Leave a Reply